March 19, 2018 H3 Biomedicine to Present at the BioCentury Annual Future Leaders in the Biotech Industry Conference Read More
February 20, 2018 H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine H3B-8800 is first known investigational therapy to target RNA splicing factor mutations, highly prevalent in many hematologic cancers Initial data… Read More
January 8, 2018 H3 Biomedicine To Present 2018 Outlook at the 36th Annual J.P. Morgan Healthcare Conference Company highlights focus on driving forward three differentiated, internally generated cancer therapies to clinical proof of concept. Read More
January 2, 2018 H3 Biomedicine to Present at the 36th Annual J.P. Morgan Healthcare Conference Read More
December 15, 2017 H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research in Hepatocellular Carcinoma Published in December Issue of Cancer Research Read More
December 9, 2017 H3 Biomedicine Advances RNA Splicing Platform through Collaborations with Key Academic Centers Presentations at 2017 American Society of Hematology Meeting Highlights Pre-Clinical Research in RNA splicing Read More
December 6, 2017 H3 Biomedicine Presents Preclinical Data on Novel ERα antagonist at San Antonio Breast Cancer Symposium Selective Estrogen Receptor Covalent Antagonist (SERCA) inactivates both wild-type and mutant ERα Read More
September 15, 2017 H3 Biomedicine to Present New Data on H3B-6527, an FGFR4 Inhibitor, at the 2017 International Liver Cancer Association Annual Meeting Presentation to highlight pre-clinical data on H3’s Lead Solid Tumor Compound Read More